Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center
|
|
|
- Jodie Hart
- 5 years ago
- Views:
Transcription
1 Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center
2 Disclosure Research Funding from BMS.
3 Learning Objectives -Define belatacept-resistant rejection - Identify pathways and cell subsets involved in belatacept-resistant rejection -Propose possible therapeutic interventions to prevent belatacept-resistant rejection
4 Current Immunosuppressive Strategies Basiliximab Thymoglobulin Campath Calcineurin Inhibitor Mycophenolate +/- Steroids Time
5 CD154 CD40 T Cell Cytokine IL-2, IL-15, IL-7 APC Steroids Signal 3 CNI X γ chain Signal 1 MMF TCR Signal 2 (+) CD28 p/mhc CD80/86
6 Targeted immunosuppression Neurotoxicity Hypertension Hyperlipidemia Near Ubiquitous Target Distribution CNI Cellcept Steroids Rapamycin Diabetes Immunosuppression Nephrotoxicity
7
8
9 Targeted immunosuppression Specifically Target T cell Immunosuppression
10 CD154 CD40 T Cell Cytokine IL-2, IL-15, IL-7 APC Signal 3 γ chain Signal 1 Signal 2 (+) (+) CD28 TCR p/mhc CD80/86
11 CTLA4 mutated human IgG1 CTLA-4 T cell IgG1 CTLA4-Ig Dimer Retains Fc binding Non-complement fixing Serum T1/2 ~2 wks Immunologic tool and therapeutic fusion protein
12 Belatacept (LEA29Y): Engineered for more potent co-stimulation blockade Extracellular portion of CTLA4 (CD152) A29 L104 Second generation CTLA4 derivative human IgG1 Fc fusion protein aa substitutions at position 29 and fold higher avidity to B7-1 4-fold higher avidity to B7-2 than parent CTLA4-Ig molecule 10-fold higher biologic potency in vitro Larsen et al AJT 2005
13
14 7yr Patient/Graft Survival
15 BENEFIT-Trial: Improved Cardiovascular, Metabolic and Renal health NEJM 2016
16 Belatacept & Rejection Acute rejection rates
17 FDA Approval 2011
18 Current Immunosuppressive Strategies Basiliximab Belatacept X Calcineurin Inhibitor Mycophenolate Steroids Time
19 % rejection
20 Update Belatacept Protocol Weeks Belatacept 10 mg/kg IV 5 mg/kg Q4wks IV Tacrolimus 5-8 ng/ml 3-5 ng/ml 3 mo 6 mo 9 mo 12 mo
21 Percent 100 Freedom from Rejection *p= Months
22 Percent 100 Patient Survival *p= Bela 2.1 (N=169) Months
23 Percent 100 Graft Survival *p= Bela 2.1 (N=169) Months
24 Renal Function On Treatment Analysis- Combined
25 Percent 100 Freedom From DSA *p= TAC: 85 Bela Months
26 Belatacept and Rejection Better long-term renal function post-transplant Higher acute rejection rate and more severe pathology Why does belatacept-resistant rejection occur? Acute rejection rates
27 Costimulation Blockade Resistant Rejection alternative costimulatory molecules provide escape signals certain T cell subsets are less dependent on traditional costimulatory signals Memory T cells acquired directly vs via heterologous response? Other cell subsets The Emory Transplant Center
28
29
30 Understanding Mechanisms of Costimulation Independence Belatacept + MMF + Steroids d0 Belatacept Resistance d140 Belatacept Susceptibility d306 Rejection Rejection
31 % Survival Understanding Mechanisms of Costimulation Independence Pre-Transplant Immune Phenotype? Belatacept + MMF + Steroids d0 Belatacept Resistance d140 Belatacept Susceptibility d306 Rejection Rejection Days Post-Transplant
32 % Survival Understanding Mechanisms of Costimulation Independence Pre-Transplant Immune Phenotype? Belatacept + MMF + Steroids d0 Belatacept Resistance d140 Belatacept Susceptibility d306 Rejection Rejection Days Post-Transplant
33 % Survival Understanding Mechanisms of Costimulation Independence Pre-Transplant Immune Phenotype? Belatacept + MMF + Steroids d0 Belatacept Resistance d140 Belatacept Susceptibility d306 Rejection Rejection Days Post-Transplant
34 % Survival Understanding Mechanisms of Costimulation Independence Days Post-Transplant
35
36
37 CD127 MFI CD28hi TEMRA P<.0001 **** CD28hi TEMRA Cells Express High Levels of IL-7Rα IL7Rα CD16 IL6st CXCR3 CCR6 IL6Rα LFA-1 VLA CD154 ICOS CD27 CD2 0 CD28hi TEMRA CD28null TEMRA TIM3 LAG3 PD1 Ox40 CD28hi TEMRA
38 The Role of IL-7Rα Signaling in Transplantation Lymphopoiesis γc IL-7Rα TCR CD28 Homeostatic Proliferation or Depletion TNF Signal 3 Cytokine? IFN GzmB Target Cell Death
39 The Role of IL-7Rα Signaling in Transplantation Lymphopoiesis γc IL-7Rα TCR CD28 Homeostatic Proliferation or Depletion TNF Signal 3 Cytokine? IFN GzmB Target Cell Death
40 The Role of IL-7Rα Signaling in Transplantation Lymphopoiesis γc IL-7Rα TCR CD28 Homeostatic Proliferation or Depletion TNF Signal 3 Cytokine? IFN GzmB Target Cell Death
41 CD28 %IFNg+TNF+ CD8 T cells Addition of IL-7 Augments Effector Function IL-7 Augments Effector Function *** ** IFNγ 0 Unstim P+I P+I+IL7 TNF IFN GzmB Target Cell Death
42 Mouse Allogeneic Skin Graft Experimental Design Balb/c Ear (R) Tail (L) C57BL/6 Donor Recipient Treatment administered via IP injection at day 0, 2, 4 and 6 anti-il7rα + Costimulation Blockade Costimulation Blockade Assess Skin Graft Survival
43 Percent survival Blocking IL-7Rα Prevents Costimulation Independent Rejection CoB vs. CoB + anti-cd P<.0001 **** 50 CoB+aIL7Ra CoB No Rx Days Post-Transplant
44 Role of IL-7Rα in Costimulation Independent Rejection C57BL/6 Ova Expressing Graft CTLA4-Ig 24 hours CTLA4-Ig+ Anti-IL7Rα Adoptive Transfer of OT1 & OTII CD4 and CD8 Graft specific T cells Untreated Thy1.1+ Tracking Graft Specific T cells
45 % survival Addition of Anti-IL-7Rα Synergistically Prevents Costimulation Independent Rejection CTLA4-Ig vs. CTLA4-Ig+anti-CD P<.0001 **** 50 No Rx CTLA4-Ig CTLA4-Ig +ail7ra Days Post-Transplant
46 Abs. # of OTII Cells Abs. # of OTI Cells Anti-IL-7Rα + CoB Results in Decreased Expansion of Graft Reactive T cells CD4 T Cells CD8 T cells 10 6 * * 10 6 * ** ** No Rx ail7rα CTLA4-Ig+aIL7Rα 10 2 No Rx ail7rα CTLA4-Ig CTLA4-Ig+aIL7Rα
47 TNF Anti-IL-7Rα+CoB Decreased Effector Function of Graft Reactive T cells CD8 T cell Effector Function % IFNg+TNF+ of OT No Rx ail7rα No Rx *** CTLA4-Ig CTLA4-Ig+aIL7Rα ail7rα CTLA4-Ig TNF IFN GzmB Target Cell Death CTLA4-Ig+aIL7Rα IFNγ
48 CD4 + CD25 + CD127 lo/- cells express highest level of Foxp3 Strongest correlation with functional activity Used as phenotype in clinical trials
49 Anti-IL-7Rα + Costimulation Blockade Impact on Graft Specific CD4 T cells Treg Phenotype IL7Rα (CD127) Negative, CD25 (IL2Rα) Positive Immune Regulation IL-10 TGFβ CTLA4 Graft Protection
50 FoxP3 %CD25+FoxP3+ of OTII Anti-IL-7Rα + Costimulation Blockade increased Frequency of Tregs * Immune Regulation 10 IL No Rx No Rx ail7rα CTLA4-Ig CTLA4-Ig+aIL7Rα ail7rα CTLA4-Ig TGFβ CTLA4 Graft Protection CTLA4-Ig+aIL7Rα CD25
51 %CD25+FoxP3+ of OTII FoxP3 CD25 Anti-IL-7Rα + CoB increased Frequency of Tregs Sustained at Day ** Immune Regulation IL-10 CTLA4 Graft Protection 0 No Rx CTLA4-Ig CTLA4-Ig+aIL7Rα No Rx CTLA4-Ig TGFβ CTLA4-Ig+aIL7Rα
52 % survival %CD25+FoxP3+ of OTII Anti-IL-7Rα + CoB increased Frequency of Tregs Sustained at Day 30 Immune Regulation IL * ** ** No Rx CTLA4-Ig CTLA4-Ig+aIL7Ra TGFβ CTLA4 Graft Protection CTLA4-Ig vs. 0CTLA4-Ig+anti-CD Days Post-Transplant P<.0001 **** 50 No Rx CTLA4-Ig CTLA4-Ig +ail7ra Days Post-Transplant
53 Costimulation Independent CD8 T cells Decrease CD28 Expression, Increase IL-7Rα CD28 CD8 OTI Thy1.1 No Rx % of Thy1.1 CD8 (OT1) No Rx CTLA4-Ig CTLA-4 Ig CD127
54 TIGIT % OTI Cells Anti-IL-7Rα + CoB Induces an Exhaustion-like Phenotype in Graft Reactive T cells CD8 OTI Thy1.1 PD1+TIGIT+ OTI T cells (Day 20) No Rx CTLA-4 Ig CTLA4-Ig+aIL7Rα 60 **** PD1 0 No Rx CTLA4-Ig TLA4-Ig+aIL7Rα
55 % Graft Survival Anti-IL7Ra+CoB Mediated Graft Survival is PD1-Dependent Dependent Survival Benefit 100 CTLA4-Ig CTLA4-Ig+aIL7Ra CTLA4-Ig+aIL7Ra+aPD1 P<.0001 **** Days Post-Transplant
56
57
58
59 CTLA-4 Next Generation Costimulation Blockade T cell function is tightly regulated by a fine balance of costimulatory and coinhibitory signals CD28
60
61 Lulizumab- a domain antibody V PEG traditional antibody (IgG) - monovalent, pegylated - non-activating - no evidence of cytokine release syndrome
62 Selective blockade of CD28 is superior to CTLA4-Ig Liu et al., 2014 J Exp Med
63 2B4 Upregulation after CD28 dab The Emory Transplant Center
64 Transplant CD28 dab Renal allograft Protocol d ultrasound biopsy CD28 dab mg/kg Anti-IL-2R Solumedrol 20mg/day 2mg/day 1mg/day MMF 15 mg bid 15 mg qd No treatment of acute rejection episodes
65 Belatacept vs CD28-specific Rx 100 Belatacept 100 anti-cd28 dab The Emory Transplant Center
66 Next Generation Costimulation Blockade CD28 selective therapy Primate studies supportive, superior to belatacept Mechanistic studies,? Increase in Treg activity Appears safe and efficacious No overt safety signal in clinical trial for SLE Next Step- Clinical Trial(s) in Renal Transplant recipients The Emory Transplant Center
67 Proposed Immunosuppression Protocol Thymoglobulin (total dose 6mg/kg) biopsy 3 mo 6 mo 9 mo 12 mo 18 mo MMF steroid 1000mg po BID 5mg CD28 dab (Lulizumab) dosing 12.5 mg weekly 12.5mg q 2wk vs Tacrolimus 8-12ng/ml 5-8ng/ml 3-5ng/ml
68 Conclusions Belatacept holds promise for improved outcomes Pre-transplant phenotyping may be able to identify patients at risk of rejection Adjunct therapies may improve outcomes blockade of IL-7 pathway, IL-15 CD28 selective therapy
Innovation In Transplantation:
Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were
T Cell Activation, Costimulation and Regulation
1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family
T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
Overview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
Liver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
Better than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct
Better than Google- Click on Immunosuppression Renal Transplant David Landsberg Oct 3 2008 OUTLINE History of Immunosuppression Trends in Immunosupression FK vs CYA Steroid Minimization CNI Avoidance Sirolimus
From Bench to Bedside Regulatory T Cells: Can We Make the Police Work for Us?
From Bench to Bedside Regulatory T Cells: Can We Make the Police Work for Us? Sang Mo Kang, MD Qizhi Tang, PhD UCSF Division of Transplantation UCSF Transplant Conference 2012 The Reality of Immunosuppression
SUPPLEMENTARY FIGURE 1
SUPPLEMENTARY FIGURE 1 A LN Cell count (1 ) 1 3 1 CD+ 1 1 CDL lo CD hi 1 CD+FoxP3+ 1 1 1 7 3 3 3 % of cells 9 7 7 % of cells CD+ 3 1 % of cells CDL lo CD hi 1 1 % of CD+ cells CD+FoxP3+ 3 1 % of CD+ T
Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
Literature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells
Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard
MECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW
MECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW YVON LEBRANCHU Service Néphrologie et Immunologie Clinique CHU TOURS ANTIGEN PRESENTING CELL CD4 + T CELL CYTOKINE PRODUCTION CLONAL
Why Do We Need New Immunosuppressive Agents
Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for
Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA
Antibody Targeting of Human CD27 with Varlilumab (CDX-1127) identifies genes and pathways related to inflammation Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA www.celldextherapeutics.com
Belatacept: An Update of Ongoing Clinical Trials
Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin Abstract Belatacept is a fusion protein
Kidney transplantation: into the future with belatacept
Kidney transplantation: into the future with belatacept Clin. Invest. (2012) 2(12), 1171 1176 Allogenic organ transplantations are limited by drug-associated toxicity and the occurrence of antibody-mediated
Interruption of OX40L signaling prevents costimulation blockade resistant allograft rejection
Interruption of OX40L signaling prevents costimulation blockade resistant allograft rejection William H. Kitchens, 1,2 Ying Dong, 1 David V. Mathews, 1 Cynthia P. Breeden, 1 Elizabeth Strobert, 2 Maria
Why we need a new paradigm in immunosuppression USHERING A NEW ERA OF IMMUNOSUPPRESSION. Causes of death and graft loss after kidney transplantation
USHERING A NEW ERA OF IMMUNOSUPPRESSION Flavio Vincenti 45 35 AR 3 (%) 25 15 5 35.7 Why we need a new paradigm in immunosuppression Incidence of early acute rejection episodes ( 6 months) 43.7 27.4 17.9
Effector T Cells and
1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New
TRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
Pathways to Protecting from Autoimmunity the Resurrected/Regenerated Beta Cells. Jeffrey Bluestone, PhD Diabetes Center at UCSF
Pathways to Protecting from Autoimmunity the Resurrected/Regenerated Beta Cells Jeffrey Bluestone, PhD Diabetes Center at UCSF Number of Transplants Is islet replacement a viable option? 2000 1800 1600
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
Immunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
E possibile creare un ambiente tollerogenico dopo il trapianto d organo utilizzando cellule staminali come se fossero farmaci?
E possibile creare un ambiente tollerogenico dopo il trapianto d organo utilizzando cellule staminali come se fossero farmaci? Giuseppe Remuzzi 1 Infections & Transplantation Varese, 18 maggio 2017 LONG
Controversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine
Immune Tolerance Kyeong Cheon Jung Department of Pathology Seoul National University College of Medicine Immune tolerance Unresponsiveness to an antigen that is induced by previous exposure to that antigen
Precision Medicine and not Individualized Therapy is Required for Successful Novel Drug Development
Precision Medicine and not Individualized Therapy is Required for Successful Novel Drug Development 1 Disclosures F Vincenti University of California San Francisco, San Francisco, United States I have
Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
Case Reports in Transplantation, Article ID 190516, 4 pages http://dx.doi.org/10.1155/2014/190516 Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration
Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
Chronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP
Chronic Kidney Disease & Transplantation Paediatrics : 2004 FRACP ANZDATA Registry Mode of First Treatment - Paediatric 14 12 10 8 6 4 2 0 0-4 y 5-9 y 10-14 y 15-19 y Hospital CAPD Hospital HD Hospital
OBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
Tolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
Supplementary Figure Legends. group) and analyzed for Siglec-G expression utilizing a monoclonal antibody to Siglec-G (clone SH2.1).
Supplementary Figure Legends Supplemental Figure : Naïve T cells express Siglec-G. Splenocytes were isolated from WT B or Siglec-G -/- animals that have not been transplanted (n= per group) and analyzed
Steroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
Literature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells
Research article Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells Chen Wang, 1 Tai Yi, 1 Lingfeng Qin, 2 Roberto A. Maldonado, 3 Ulrich H. von Andrian, 3
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
Potential Catalysts in Therapeutics
LIVER TRANSPLANTATION 20:S22 S31, 2014 SUPPLEMENT Potential Catalysts in Therapeutics Bruce A. Luxon Division of Gastroenterology-Hepatology, University of Iowa, Iowa City, IA Received July 23, 2014; accepted
SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School
VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:
John Langowski, Ph.D. Nektar Therapeutics San Francisco, CA USA
NKTR-38: a selective, first-in-class IL-2 pathway agonist which increases number and suppressive function of regulatory T cells for the treatment of immune inflammatory disorders John Langowski, Ph.D.
NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity
NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging
Cases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center
Cases: CMV, HCV, BKV and Kidney Transplantation Simin Goral, MD University of Pennsylvania Medical Center Disclosures Grant support: Otsuka Pharmaceuticals, Astellas Pharma, Angion, AstraZeneca, and Kadmon
Restoring Immune Function of Tumor-Specific CD4 + T Cells during Recurrence of Melanoma
Restoring Immune Function of Tumor-Specific CD4 + T Cells during Recurrence of Melanoma Goding SR et al. J Immunol 2013; 190:4899-4909 C. Nikolowsky Christian Doppler Laboratory for Cardiac and Thoracic
Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response
Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. Mechanisms of Immune Tolerance ACTIVATION (immunity) SUPPRESSION (tolerance)
Mechanisms of Immune Tolerance
Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. ACTIVATION (immunity) SUPPRESSION (tolerance) Autoimmunity Immunodeficiency
Induction of donor-specific hyporesponsiveness after renal. transplantation. Long term follow-up
Induction of donor-specific hyporesponsiveness after renal transplantation. Long term follow-up Marc Lúcia, Oriol Bestard, Marcel la Franquesa, Josep M Cruzado, Montse Gomà, Núria Bolaños, Gema Cerezo,
Tim-3 as a target for tumor immunotherapy
Tim-3 as a target for tumor immunotherapy Ana Carrizosa Anderson Brigham and Women s Hospital Harvard Medical School Disclosures A portion of the work has been performed as part of a sponsored research
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
FIT Board Review Corner March 2016
FIT Board Review Corner March 2016 Welcome to the FIT Board Review Corner, prepared by Sarah Spriet, DO, and Tammy Peng, MD, senior and junior representatives of ACAAI's Fellows-In-Training (FITs) to the
T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
Immunological Tolerance
Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for
NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology
plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017
Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
T-cell Exhaustion in Leukemia Relapse Post Allogeneic Stem Cell Transplantation
T-cell Exhaustion in Leukemia Relapse Post Allogeneic Stem Cell Transplantation Hong Zheng, M.D., Ph.D. Assistant Professor of Medicine Penn State Hershey Cancer Institute Penn State University College
Treatment of Chronic Antibody Mediated Rejection
Treatment of Chronic Antibody Mediated Rejection Robert A. Montgomery MD, DPhil Professor of Surgery Director of the NYU Langone Transplant Institute Disclosures: Served on Advisory Boards for Genentech
Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF
Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases Abul K. Abbas UCSF Balancing lymphocyte activation and control Activation Effector T cells Tolerance Regulatory T cells
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
Lionel Rostaing, Nassim Kamar: Alefacept and Transplantation. Alefacept Treatment in the Setting of Transplantation
Trends in Transplant. 2014;8:35-40 Lionel Rostaing, Nassim Kamar: Alefacept and Transplantation Alefacept Treatment in the Setting of Transplantation Lionel Rostaing and Nassim Kamar Department of Nephrology
Identification of novel immune regulators of tumor growth using highthroughput
Identification of novel immune regulators of tumor growth using highthroughput screening in vivo Tom Brennan 1 Five Prime s Unique Platform Tests Nearly Every Extracellular Protein to Identify Protein
Desensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
DSA Positive and then To biopsy or not?
DSA Positive and then To biopsy or not? Banff SCT 2017 29 March 2017 Peter Nickerson, MD, FRCPC, FCAHS Flynn Family Chair in Renal Transplantation Professor of Internal Medicine and Immunology Relevant
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
T cell maturation. T-cell Maturation. What allows T cell maturation?
T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry
2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
T Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009
T Cell Activation Patricia Fitzgerald-Bocarsly March 18, 2009 Phases of Adaptive Immune Responses Phases of T cell responses IL-2 acts as an autocrine growth factor Fig. 11-11 Clonal Expansion of T cells
Tolerance 2. Regulatory T cells; why tolerance fails. FOCiS. Lecture outline. Regulatory T cells. Regulatory T cells: functions and clinical relevance
1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails
Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
Class I Ag processing. TAP= transporters associated with antigen processing Transport peptides into ER
Antigen processing Class I Ag processing TAP= transporters associated with antigen processing Transport peptides into ER Proteosome degrades cytosolic proteins Large, multi-subunit complex Degrades foreign
Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy
Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy Joshua M Rosenblum, Emory University Allan Kirk, Emory University Journal Title: Immunological Reviews
Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways
Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways Shihua Lin, PhD. Senior Scientist Analytical Biotechnology Development, MedImmune
Challenges)facing)An./tumour) Immunotherapy)in)Myeloma)))
Challenges)facing)An./tumour) Immunotherapy)in)Myeloma))) Immune Dysfunction Prof)Gordon)Cook) Leeds)Ins.tute)of)Cancer)&)Pathology) University)of)Leeds) Impaired)immunity)in)MM) )clinical) % of Infection-related
Therapeutic PD L1 and LAG 3 blockade rapidly clears established blood stage Plasmodium infection
Supplementary Information Therapeutic PD L1 and LAG 3 blockade rapidly clears established blood stage Plasmodium infection Noah S. Butler, Jacqueline Moebius, Lecia L. Pewe, Boubacar Traore, Ogobara K.
Tolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS
1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails
Immune Regulation and Tolerance
Immune Regulation and Tolerance Immunoregulation: A balance between activation and suppression of effector cells to achieve an efficient immune response without damaging the host. Activation (immunity)
Transplant Overview. Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005
Transplant Overview Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005 CTI Clinical Trial and Consulting Services Drug Development Company focused in key
Chapter 10 (pages ): Differentiation and Functions of CD4+ Effector T Cells Prepared by Kristen Dazy, MD, Scripps Clinic Medical Group
FIT Board Review Corner September 2015 Welcome to the FIT Board Review Corner, prepared by Andrew Nickels, MD, and Sarah Spriet, DO, senior and junior representatives of ACAAI's Fellows-In-Training (FITs)
Alemtuzumab-based induction treatment versus basiliximab based induction treatment in kidney transplantation (the 3C Study): a randomised trial
Alemtuzumab-based induction treatment versus basiliximab based induction treatment in kidney transplantation (the 3C Study): a randomised trial Journal club Feb 2014 Background and Rationale Despite substantial
Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
C M. Chimerigen Laboratories C M. Biologically Active BULK Proteins. Butyrophilin-like 2 [BTNL2] mil-35/fc An Inhibitory Cytokine.
![C M. Chimerigen Laboratories C M. Biologically Active BULK Proteins. Butyrophilin-like 2 [BTNL2] mil-35/fc An Inhibitory Cytokine.](/thumbs/95/123073381.jpg "C M. Chimerigen Laboratories C M. Biologically Active BULK Proteins. Butyrophilin-like 2 [BTNL2] mil-35/fc An Inhibitory Cytokine.")
www.adipogen.com 2014 fusion Proteins Laboratories The Experts for High Quality Fusion Proteins NEW NEW Butyrophilin-like 2 [BTNL2] Butyrophilin-like 2 (BTNL2) is a butyrophilin family member with homology
IMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar
IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences
Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients
Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients A Skaro, A LeFever, J Mathew, L Gallon, J Hie, C Hansen, D Stare, G Johnson, J Leventhal
Fellows Conference 01/21/2016
Fellows Conference 01/21/2016 Outline Basics of transplantation Benefits of transplantation Immunosuppressive medications Anatomy of Renal Transplantation Recipient Selection General medical condition.
SEVENTH EDITION CHAPTER
Judy Owen Jenni Punt Sharon Stranford Kuby Immunology SEVENTH EDITION CHAPTER 16 Tolerance, Autoimmunity, and Transplantation Copyright 2013 by W. H. Freeman and Company Immune tolerance: history * Some
Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
Diagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape
Diagnosis and Management of Acute and Chronic Humoral Rejection Lars Pape Immunosuppression Acute rejection Chronic rejection Side effects Infections Nephrotoxicity Adult population Nearly all late rejection-related
Harnessing tolerance mechanisms with monoclonal antibodies Prof. Herman Waldmann
Harnessing tolerance mechanisms Herman Waldmann Sir William Dunn School of Pathology, Oxford University, UK 1 1. Transplantation 2 Lymphocyte depletion strategies to minimise drug immunosuppression in
BK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia
Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia Immunosuppression in kidney transplantation Aljoša Kandus Renal Transplant Center, Department
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
Heterologous Immunity Triggered by a Single, Latent Virus in Mus musculus: Combined Costimulation- and Adhesion- Blockade Decrease Rejection
Heterologous Immunity Triggered by a Single, Latent Virus in Mus musculus: Combined Costimulation- and Adhesion- Blockade Decrease Rejection Jonathan M. Beus, Emory University Salila S. Hashmi, Emory University
Costimulation blockade for prevention of
Costimulation blockade for prevention of acute GVHD Amelia Langston, MD Professor of Hematology & Medical Oncology Medical Director, Emory University BM & Stem Cell Transplant Center Emory University School
BK Viral Infection and Malignancy in Renal Transplantation ~A Case History~
BK Viral Infection and Malignancy in Renal Transplantation ~A Case History~ Mariko Toyoda, MD Department of Nephrology, Japanese Red Cross Kumamoto Hospital Statement of Disclosure The author does not